MTX-13, a novel PTK7-directed ADC, has demonstrated anticancer activity and the ability to overcome tumor resistance in pan-PTK7+ tumors and has the potential to outperform PF-06647020 in clinical trials (44). This evidence concerns the gene PTK7 and neoplasm.